Contact Affinity for availability of Kininogen Antibody Products

High Molecular Weight – HMW Kininogen Antibodies

Affinity Biologicals, Inc. manufactures a broad range of High Molecular Weight – HMW Kininogen Antibodies which can be found in the listing below.   Further information about each individual Kininiogen antibody is available by following the associated links.  Our High Molecular Weight – HMW Kininogen Antibodies are excellent for use in immunoassays where high sensitivity is required and are frequently the preferred reagent for immunopreciptaion techniques and activity neutralization assays.  These antibodies have proven to be extremely useful in the preparation of immune-adsorbent resins for use in immuno-depletion of specific proteins from plasma as well as immuno-affinity purification of proteins.  Affinity’s High Molecular Weight – HMW Kininogen Antibodies are manufactured for use in research applications.

Listing for High Molecular Weight – HMW Kininogen Antibodies

    Description of Kininogen

    Kininogens are multi-function proteins that are involved in the processes of coagulation, anticoagulation, fibrinolysis, inflammation and cell adhesion. Kininogens are produced in the liver but have also been found in platelets, granulocytes, renal tubular cells and skin. Two forms of kininogen are identified in plasma, both of which are the result of differential splicing of a single gene. High molecular weight kininogen (HK), previously known as Fitzgerald Factor, is a single chain glycoprotein of 120 kDa with a plasma concentration of 80 μg/mL (660 nM). Low molecular weight kininogen (LK), also known as α-cysteine protease inhibitor, is a single chain glycoprotein of 68 kDa with a plasma concentration of 160 μg/mL (2.35 μM). HK and LK share a common heavy chain and bradykinin domain, but have unique light chains. It is the light chain of HK that is responsible for the coagulant cofactor activity by binding to anionic surfaces and for the ability to bind the zymogens prekallikrein (PK) and factor XI (FXI). HK is cleaved by kallikrein in several sequential steps that result in the release of a potent vasodilator bradykinin and the conversion to a two-chain form of HK with increased cofactor activity. In plasma, most of the PK and FXI circulate in complex with HK. Activation of PK by FXIIa generates kallikrein, which initiates reciprocal activation of PK and FXI. The presence of HK also serves to protect kallikrein and activated FXI from protease inhibitors such as C1-Inhibitor, but regulation of the system may be accomplished through proteolytic inactivation of the HK cofactor activity by these enzymes.1-2

    References and Reviews

    1. Coleman RW, Schmaier AH; Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive and Proinflammatory Attributes. Blood 90, pp 3819-3843, 1997.
    2. DeLa Cadena R, Watchtfogel YT, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 219-240, J.B. Lippincott Co., Philadelphia, 1994.